AbbVie's Wrinkle Drug TrenibotE Rejected by FDA Over Manufacturing Issues

The FDA issued a Complete Response Letter to AbbVie due to manufacturing concerns with the TrenibotE wrinkle drug. In a separate development, the company made a $1.4 billion investment in a new manufacturing campus to support production of several medicines.

AbbVie received a setback as the FDA rejected its TrenibotE wrinkle drug application due to manufacturing process concerns as mentioned in a Complete Response Letter . This news contrasts with other developments in the company's pipeline, including its plans to invest $1.4 billion in a new North Carolina manufacturing campus to support the production of immunology, neuroscience, and oncology medicines.

This investment underlines AbbVie's ongoing commitment to expanding its pharmaceutical production capabilities. By broadening these operations, the company aims to increase the availability of its existing drugs and potentially new ones in the future.

A recent FDA approval for another biologic, Dupixent, from a collaborating company expanded its application, further underscoring the rapidly evolving treatment landscape .